It is the policy of the American College of Physicians (ACP) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. To this end, and consistent with the policies of the ACP and the Accreditation Council of Continuing Medical Education (ACCME), all those in a position to control the content for all ACP continuing medical education activities are required to disclose any relationships with entities whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Faculty are asked to use generic names in their discussion of therapeutic options. If trade-name products manufactured by companies with whom they have relationships are to be discussed, faculty are asked to provide evidence-based citations in support of the discussion. This information is reviewed by individuals who have oversight for portions of the scientific program, and, if necessary, adjustments are made to the topic or faculty to balance the discussion. Further, all participants are asked to evaluate each session for commercial bias so that future decisions about content and faculty are made in light of this information.